Targeting MAPK Signalling: Prometheus Fire or Pandoras Box?

Author(s): Simone Boldt, Walter Kolch

Journal Name: Current Pharmaceutical Design

Volume 10 , Issue 16 , 2004

Become EABM
Become Reviewer


MAPK (Mitogen Activated Protein Kinase) pathways mediate fundamental biological processes and have moved into the limelight of drug discovery during the past decade. Here we review the biochemistry and biology of MAPK signalling with a focus on ERK, JNK and p38. We summarise current drug discovery efforts and clinical trials. Further, we critically discuss the rationale behind current strategies of using MAPK pathways as drug targets and suggest new approaches that take the complexity of MAPK signalling networks into account.

Keywords: mitogen activated protein kinase, erk, jnk, p38, signal transduction, drug discovery, clinical trials

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2004
Page: [1885 - 1905]
Pages: 21
DOI: 10.2174/1381612043384420
Price: $65

Article Metrics

PDF: 6